BIOAFFINITY TECHNOLOGIES, INC.

NASDAQ: BIAF (bioAffinity Technologies, Inc.)

Kemas kini terakhir: 08 Nov, 5:47PM

2.06

0.01 (0.49%)

  • 1H 0.49%
  • 5H 37.33%
  • 1B -1.44%
  • 6B -76.07%
  • Tahun Ke Tarikh -92.70%
  • 1T -93.64%
  • 5T -99.17%
Penutupan Terdahulu 2.05
Buka 2.01
Jumlah Dagangan 138,441
Purata Dagangan (3B) 2,824,781
Modal Pasaran 9,267,340
Harga / Jualan (P/S) 0.170
Harga / Buku (P/B) 0.820
Julat 52 Minggu
1.91 (-7%) — 46.53 (2158%)
Tarikh Pendapatan 14 Aug 2025
Margin Keuntungan -110.55%
Margin Operasi (TTM) -141.73%
EPS Cair (TTM) -0.710
Pertumbuhan Hasil Suku Tahunan (YOY) -23.00%
Jumlah Hutang/Ekuiti (D/E MRQ) 92.48%
Nisbah Semasa (MRQ) 0.550
Aliran Tunai Operasi (OCF TTM) -6.56 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -2.98 M
Pulangan Atas Aset (ROA TTM) -88.58%
Pulangan Atas Ekuiti (ROE TTM) -290.85%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Diagnostics & Research (US) Menaik Bercampur
Diagnostics & Research (Global) Menaik Bercampur
Stok bioAffinity Technologies, Inc. Bercampur Bercampur

AISkor Stockmoo

0.1
Konsensus Penganalisis 2.0
Aktiviti Orang Dalam NA
Volatiliti Harga 0.5
Purata Bergerak Teknikal 0.0
Osilator Teknikal -2.0
Purata 0.13

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
BIAF 9 M - - 0.820
ICLR 14 B - 24.22 1.52
OPK 1 B - - 0.790
FLGT 954 M - - 0.760
PSNL 953 M - - 4.95
MYGN 711 M - - 1.90

bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company’s product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
Sektor Healthcare
Industri Diagnostics & Research
Gaya Pelaburan Small Value
% Dimiliki oleh Orang Dalam 24.53%
% Dimiliki oleh Institusi 1.80%

Tiada data dalam julat masa ini.

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
03 Dec 2025 Pengumuman bioAffinity Technologies’ Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable
14 Nov 2025 Pengumuman bioAffinity Technologies Reports Third Quarter 2025 Financial Results
05 Nov 2025 Pengumuman bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume
28 Oct 2025 Pengumuman bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases
20 Oct 2025 Pengumuman bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025
16 Oct 2025 Pengumuman bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer
15 Oct 2025 Pengumuman bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
09 Oct 2025 Pengumuman WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
09 Oct 2025 Pengumuman bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
08 Oct 2025 Pengumuman bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
08 Oct 2025 Pengumuman WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
07 Oct 2025 Pengumuman bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025
30 Sep 2025 Pengumuman WallachBeth Capital Announces Closing of bioAffinity Technologies Public Offering for $4.8m
30 Sep 2025 Pengumuman bioAffinity Technologies Announces Closing of $4.8 Million Public Offering
29 Sep 2025 Pengumuman WallachBeth Capital Announces Pricing of bioAffinity Technologies Public Offering for $4.8m
29 Sep 2025 Pengumuman bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering
26 Sep 2025 Pengumuman bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath® Lung
17 Sep 2025 Pengumuman bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025
09 Sep 2025 Pengumuman Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda